NCT07106931 Early STratification of Acute ARThritis
| NCT ID | NCT07106931 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Diakonhjemmet Hospital |
| Condition | Arthritis |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2024-11-05 |
| Primary Completion | 2044-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2024-11-05 with a primary completion date of 2044-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The prospective observational study "Early STratification of acute inflammatory ARThritis" (START) aims to build a platform for identification of markers for early stratification of inflammatory arthritis to ensure timely diagnosis and correct initial treatment. Management of early-stage inflammatory arthritis is a daily challenge for the rheumatologist and encompasses a range of conditions. Stratification is needed both for optimal diagnostics and for personalising therapy, but is hampered by a lack of tools. Current evaluation is inadequate for early diagnosis and treatment of inflammatory joint diseases as well as for timely diagnosis of infections. The clinical role of novel biomarkers needs to be investigated in large patient samples. In the START study, an extensive data collection will be performed to build a platform for identification and validation of biomarkers for stratification of early-stage inflammatory arthritis. The study has an ambitious goal of improving patient care by increased understanding of the disease. The project applies a unique multitude of approaches to characterisation of patients, including modern imaging techniques, analyses of synovial fluid and -biopsies, genetic and epigenetic markers, proteomics, microbiota analyses and immunological markers. The results will enable clinicians to make better informed treatment decisions for the individual patient with early-stage inflammatory arthritis.
Eligibility Criteria
Inclusion Criteria: * Arthritis\* in one or more joints of less than 12 weeks' duration\*\* * Adult patients (\> 18 years) capable of understanding and signing an informed consent form * Defined as currently active clinical synovitis (ie, swelling) in at least one joint as determined by an expert assessor which might be confirmed by ultrasonography \*\* Prior patient reported swollen joint not confirmed as arthritis by a rheumatologist is not an exclusion Exclusion Criteria: * Swollen joint related to trauma * Subject not capable of adhering to the study protocol
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07106931 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Arthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07106931 currently recruiting?
Yes, NCT07106931 is actively recruiting participants. Contact the research team at s.w.syversen@gmail.com for enrollment information.
Where is the NCT07106931 trial being conducted?
This trial is being conducted at Oslo, Norway.
Who is sponsoring the NCT07106931 clinical trial?
NCT07106931 is sponsored by Diakonhjemmet Hospital. The trial plans to enroll 400 participants.